Results 1 to 10 of about 4,325 (116)

Renoprotective effect of tolvaptan in patients with new-onset acute heart failure

ESC Heart Failure, 2020
Aims Although tolvaptan has been reported to prevent worsening renal function (WRF) in patients with advanced acute heart failure (AHF), evidence regarding the effect of tolvaptan on renal function in patients with new‐onset AHF is not available.
Kenichi Fujii, Koichiro Matsumura, Munemitsu Otagaki   +2 more
exaly   +2 more sources

Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan [PDF]

Medicina
Background and Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease, and the only approved pharmacological therapy shown to slow disease progression is tolvaptan.
Zofia Jankowska, Mariusz Niemczyk
doaj   +2 more sources

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

PLoS ONE, 2022
Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction.
Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino   +8 more
doaj   +2 more sources

In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan

Journal of Pharmacological Sciences, 2022
Tolvaptan is an orally active vasopressin V2 receptor antagonist and used for the treatment of volume overload in some disease as an aquaretic. Tolvaptan sodium phosphate (OPC-61815) is a pro-drug of tolvaptan that was designed to improve water ...
Hiroyuki Fujiki, Masayuki Matsunaga, Masayuki Furukawa, Tatsuya Yamashita, Shigeki Nakamura, Toshiki Miyazaki, Hiroshi Mizuguchi, Yasuhiro Menjo, Takakuni Matsuda, Yoshihisa Yamada   +9 more
doaj   +1 more source

The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry

ESC Heart Failure, 2023
Aims The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated.
Ryusuke Nishikawa, Takao Kato, Takeshi Morimoto, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Neiko Ozasa, Tomohisa Tada, Hiroki Sakamoto, Yuta Seko, Masayuki Shiba, Yusuke Yoshikawa, Yugo Yamashita, Takeshi Kitai, Ryoji Taniguchi, Moritake Iguchi, Kazuya Nagao, Takafumi Kawai, Akihiro Komasa, Yuichi Kawase, Takashi Morinaga, Mamoru Toyofuku, Yutaka Furukawa, Kenji Ando, Kazushige Kadota, Yukihito Sato, Koichiro Kuwahara, Takeshi Kimura, for the KCHF Study Investigators   +29 more
doaj   +1 more source

Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan

ESC Heart Failure, 2021
Aims Real‐world data on the use of tolvaptan, an oral selective vasopressin 2 receptor antagonist, for patients with heart failure (HF) are not available in Western countries because tolvaptan is not indicated in the Western countries for volume overload
Takashi Kuragaichi, Yukihito Sato
doaj   +1 more source

Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan

Scientific Reports, 2021
Within no definite diuretic protocol for acute heart failure (AHF) patients and its variation in regional clinical guidelines, the latest national guidelines in Japan commends use of tolvaptan in diuretic-resistant patients.
Yusuke Yamazaki, Yasuyuki Shiraishi, Shun Kohsaka, Yuji Nagatomo, Keiichi Fukuda, Takashi Kohno, Tsutomu Yoshikawa   +6 more
doaj   +1 more source

Tolvaptan response predictors in acute heart failure patients with congestion [PDF]

Pharmaceutical Sciences Asia, 2022
Tolvaptan has been used in many countries as an adjunct to diuretic therapy for heart failure. The identification of predictors of response to tolvaptan is essential in developing individual treatment plans, and this study therefore aims to identify ...
Hindun Wilda Risni, Rani Sauriasari, Oriza Satifa   +2 more
doaj   +1 more source

Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice

European Journal of Histochemistry, 2022
Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan, Hong Zhu, Yingxia He, Qinqin Wu, Xiaoyu Duan   +4 more
doaj   +1 more source

Effectiveness of Tolvaptan Treatment in Hyponatremic Patients

Turkish Journal of Internal Medicine, 2020
Objective: Non-peptide vasopressin receptor antagonists (vaptans) are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients.
Mehmet Fethullah Aydın, Alparslan Ersoy, Mahmut Yavuz, Emel Isıktas Sayılar, Yavuz Ayar   +4 more
doaj   +1 more source